- Invest in the HMRC approved, the o2h Knowledge Intensive EIS fund which allows you to carry back EIS tax relief to 2022/23, or the benefit of investing in this current year, deadline 05th April, 2024 (capital at risk, depending on individual circumstances)
- Two part investment focus of Access & Incubation, providing unique opportunities and reducing investment risk by being deeply involved.
- Aiming to build a diverse portfolio for investors with an initial Portfolio of 5-10 unquoted and/or AIM-listed companies.
| HRMC Approved | Yes |
|---|---|
| Fund Status | Open, Closing on 05th April 2025 |
| Fund Size | Target £10m |
| Current AUM | £3.2m |
| Total Manager's AUM | £8.05m |
| Expected Exit | 3-7 years |
| Founder's Investment | Minimum 10% of every investment |
EIS tax relief is very attractive for UK tax payers
You invest £50k
EIS gives you £15k tax relief from HMRC
EIS gives you £25k tax relief from HMRC
Investment now worth £100k
£50k profit
£15k income tax relief
£10k performance incentive
£55k net profit
Investment still worth £50k
£0 profit
£15k income tax relief
£0 performance incentive
£15k net profit
Investment now worth £0
£50k loss
£15k income tax relief
£15,750 loss relief *
£0 performance incentive
£19,250 capital loss
* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees
*Tax relief depends on an individual’s circumstances and may change in the future.
- +History in grassroots science
-
We have a track record of nurturing and investing in emerging life science and tech companies – the o2h ventures team are leaders in the biotech community and have been involved as investors, holding various board/industry positions awe well as being engaged in grassroot scientific activity for over 20 years.
- +Evaluation
- +Access to scientific talents
- +Business model
our portfolio
Sorry, no results found with this search
- o2h Ventures Named Runner-Up for Best EIS Investment Manager — Specialist at the 2025 Growth Investor Awards 13 November, 2025
- o2h Ventures Participates in Oversubscribed Seed Round to Advance CamGene Therapeutics’ RNA-Based Medicines 3 November, 2025
- o2h Ventures Portfolio Update: Monument Therapeutics Reaches Landmark Milestone in Schizophrenia 23 August, 2025








